Purple Biotech Ltd (PPBT) Short-Term Debt to Equity

Purple Biotech (PPBT) adheres to ESG principles in its molecular research, strictly controlling the processing of toxic waste and patient privacy. This chart of the debt-to-equity ratio change is 0.01. The company utilizes its accumulated capital to develop inhibitors for advanced stages of the disease. Management aims to overcome tumor resistance by integrating cutting-edge developments into broad medical practice.

Purple Biotech is advancing molecular oncology while adhering to strict ESG waste disposal standards, where the ratio of liabilities due within one year to equity determines current liquidity. This coefficient measures the company's reliance on short-term debt financing, allowing GURU.Markets experts to assess default risk or the efficiency of operational resource management through the dynamics of the short-term debt-to-equity structure.